Relative Bioavailability of Two Newly Developed Tablet Formulations (TF2 and iFF) Compared to BI 1060469 TF1 Formulation, Following Oral Administration (Low and High Dose) in Healthy Female Subjects (an Open-label, Randomised, Single-dose, Three-period, Three-sequence Crossover Study at Two Different Dose Strengths)
Phase of Trial: Phase I
Latest Information Update: 28 Sep 2015
At a glance
- Drugs BI 1060469 (Primary)
- Indications Asthma
- Focus Pharmacokinetics
- Sponsors Boehringer Ingelheim
- 23 Sep 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 13 Aug 2015 Status changed from recruiting to active, no longer recruiting as per ClinicalTrials.gov record.
- 12 May 2015 New trial record